Form 4: Fulgent Genetics COO Boosts Stake via RSU Vesting
Insider Transaction Report
Fulgent Genetics' President and COO, Jian Xie, increased his beneficial ownership through the vesting of restricted stock units and a new grant, alongside tax-related share withholdings.
Summary
- Jian Xie, President and COO of Fulgent Genetics, Inc. (FLGT), reported changes in his beneficial ownership of common stock.
- On February 23, 2026, 655 shares were withheld from Xie to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) granted on February 23, 2023, at a price of $23.01 per share.
- On February 24, 2026, Xie acquired 5,862 shares from the vesting of performance-based RSUs granted on February 23, 2023.
- On February 24, 2026, Xie acquired 15,299 shares from the vesting of performance-based RSUs granted on February 26, 2024.
- On February 24, 2026, Xie acquired 27,341 shares from the vesting of performance-based RSUs granted on February 25, 2025.
- Also on February 24, 2026, a total of 26,168 shares (3,163 + 8,254 + 14,751) were withheld from Xie to satisfy tax obligations related to the vesting of the performance-based RSUs from the 2023, 2024, and 2025 grants, at a price of $23.09 per share.
- On February 24, 2026, Xie received a new grant of 31,962 restricted stock units, which will vest over a period of three years, starting March 1, 2026.
- Following these transactions, Xie's direct beneficial ownership increased to 385,679 shares.
- Additionally, 220,816 shares are indirectly beneficially owned through The Hsieh Family Dynasty Trust, dated January 27, 2010, where Mr. Xie serves on the investment committee.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a key executive's continued commitment to the company through increased equity ownership and the achievement of performance milestones leading to RSU vesting.
Positives
- Significant vesting of performance-based restricted stock units indicates the achievement of company milestones.
- A new grant of 31,962 restricted stock units demonstrates continued commitment and incentive for the President and COO.
- Increased direct beneficial ownership by a key executive aligns management interests with shareholders.
Negatives
- Shares were withheld to cover tax obligations, which is a standard practice but reduces the net shares received by the executive.
Future Outlook
The newly granted 31,962 restricted stock units will vest over a three-year period, with one-third vesting 12 months after March 1, 2026, and one-twelfth vesting every three months thereafter, contingent on continued service.
Management Comments
- Jian Xie serves on the investment committee of The Hsieh Family Dynasty Trust and disclaims any beneficial interest except with respect to any pecuniary interest therein.
Industry Context
StockSavvy.ai notes that executive compensation, particularly through equity grants like RSUs, is a common practice in the biotechnology and diagnostics industry to align executive incentives with long-term company performance and shareholder value. The vesting of performance-based units suggests the company met specific operational or financial targets.
Related Party Transactions
- Jian Xie indirectly beneficially owns 220,816 shares through The Hsieh Family Dynasty Trust, dated January 27, 2010, where he serves on the investment committee. He disclaims beneficial interest except for pecuniary interest.
Stakeholder Impact
- Shareholders: Increased alignment of executive interests with shareholder value through higher insider ownership. The vesting of performance-based RSUs suggests the company met certain targets, which could be positive for shareholders.
- Employees: The RSU grants and vesting demonstrate the company's compensation structure for key executives, potentially influencing employee morale and retention strategies.
Next Steps
- Continued vesting of the 31,962 restricted stock units over the next three years, starting March 1, 2026.
- Future disclosures of insider transactions as additional RSUs vest or other equity transactions occur.
Key Dates
| Date | Description |
|---|---|
| 2010-01-27 | Date of The Hsieh Family Dynasty Trust establishment. |
| 2023-02-23 | Grant date for certain restricted stock units, with vesting reported on this Form 4. |
| 2023-02-27 | Date original Form 4 was filed reporting the February 23, 2023 grant. |
| 2024-02-26 | Grant date for certain performance-based restricted stock units, with vesting reported on this Form 4. |
| 2025-02-25 | Grant date for certain performance-based restricted stock units, with vesting reported on this Form 4. |
| 2026-02-23 | Vesting date for restricted stock units granted on February 23, 2023, and associated tax withholding. |
| 2026-02-24 | Vesting date for performance-based restricted stock units from 2023, 2024, and 2025 grants, new RSU grant, and associated tax withholdings. |
| 2026-02-25 | Signature date of the reporting person's attorney-in-fact. |
| 2026-03-01 | Start date for the three-year vesting period of the newly granted restricted stock units. |
Keywords
Fulgent Genetics, FLGT, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Jian Xie, Beneficial Ownership, Performance-based RSUs
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.